PMID- 34213584
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220224
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Linking)
VI  - 39
IP  - 12
DP  - 2021 Dec
TI  - Escherichia coli Nissle 1917 as adjuvant therapy in patients with chronic 
      bacterial prostatitis: a non-blinded, randomized, controlled trial.
PG  - 4373-4379
LID - 10.1007/s00345-021-03773-8 [doi]
AB  - PURPOSE: To evaluate the efficacy and safety of Escherichia coli Nissle 1917 
      (EcN) in association with levofloxacin in patients with chronic bacterial 
      prostatitis (CBP). METHODS: Patients with CBP referred to our clinic from 
      September 2017 to July 2019 were enrolled. At baseline, the symptomatology was 
      assessed with the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI), while the 
      Meares-Stamey test was used to diagnose the infection. Patients were randomized 
      (1:1) in two groups (A and B). All subjects underwent oral administration of 
      Levoxacin(R) 500 mg once daily for 4 weeks. Only the patients in Group B underwent 
      oral administration of EcN(R) 320 mg, twice daily for 4 weeks and then once daily 
      for 8 weeks. After 3 months, each patient repeated the NIH-CPSI questionnaire, 
      while the Meares-Stamey test was repeated at 3 and 6 months in patients who 
      reported persistent symptoms. All adverse events (AEs) were recorded. RESULTS: A 
      total of 110 patients were enrolled. After 3 months patients in Group B reported 
      a significantly lower NIH-CPSI score (5.85 +/- 3.07 vs. 7.64 +/- 3.86; p = 0.009) and 
      biological recurrences rate (9.8 vs. 26.9%; p = 0.043). At 6 months the 
      biological recurrences rate was significantly lower in Group B (8.7 vs. 28.9%; 
      p = 0.038). Only three patients in Group A and six in Group B (p = 0.25) 
      complained mild AEs. CONCLUSIONS: Combination therapy with EcN and levofloxacin 
      allows a better control of symptoms and biological recurrences in patients with 
      CBP, without worsening the safety of the treatment.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Manfredi, Celeste
AU  - Manfredi C
AD  - Urology Unit, Department of Woman Child and of General and Specialist Surgery, 
      University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, 
      Italy.
FAU - Calace, Francesco P
AU  - Calace FP
AUID- ORCID: 0000-0002-6340-4403
AD  - Urology Unit, Department of Woman Child and of General and Specialist Surgery, 
      University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, 
      Italy. frap.calace@gmail.com.
FAU - Fusco, Ferdinando
AU  - Fusco F
AD  - Urology Unit, Department of Woman Child and of General and Specialist Surgery, 
      University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, 
      Italy.
FAU - Quattrone, Carmelo
AU  - Quattrone C
AD  - Urology Unit, Department of Woman Child and of General and Specialist Surgery, 
      University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, 
      Italy.
FAU - Giordano, Dario
AU  - Giordano D
AD  - Urology Unit, Department of Woman Child and of General and Specialist Surgery, 
      University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, 
      Italy.
FAU - Crocetto, Felice
AU  - Crocetto F
AD  - Department of Urology, University "Federico II", Naples, Italy.
FAU - Creta, Massimiliano
AU  - Creta M
AD  - Department of Urology, University "Federico II", Naples, Italy.
FAU - De Sio, Marco
AU  - De Sio M
AD  - Urology Unit, Department of Woman Child and of General and Specialist Surgery, 
      University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, 
      Italy.
FAU - Arcaniolo, Davide
AU  - Arcaniolo D
AD  - Urology Unit, Department of Woman Child and of General and Specialist Surgery, 
      University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210702
PL  - Germany
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
RN  - 0 (Anti-Bacterial Agents)
RN  - 6GNT3Y5LMF (Levofloxacin)
SB  - IM
CIN - Nat Rev Urol. 2021 Aug;18(8):444. PMID: 34253903
MH  - Adolescent
MH  - Adult
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Bacterial Infections/*therapy
MH  - Chronic Disease
MH  - Combined Modality Therapy
MH  - *Escherichia coli
MH  - Humans
MH  - Levofloxacin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prostatitis/*microbiology/*therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Chronic bacterial prostatitis
OT  - EcN
OT  - Escherichia coli Nissle
OT  - Fluoroquinolones
OT  - Microbiota
EDAT- 2021/07/03 06:00
MHDA- 2022/02/25 06:00
CRDT- 2021/07/02 12:18
PHST- 2021/04/20 00:00 [received]
PHST- 2021/06/21 00:00 [accepted]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/07/02 12:18 [entrez]
AID - 10.1007/s00345-021-03773-8 [pii]
AID - 10.1007/s00345-021-03773-8 [doi]
PST - ppublish
SO  - World J Urol. 2021 Dec;39(12):4373-4379. doi: 10.1007/s00345-021-03773-8. Epub 
      2021 Jul 2.